|
London, UK Business News
|
Home | Submit Press Release | Advertise | Submit Website
(EMAILWIRE.COM, June 22, 2017 ) Europe Generic drugs market was worth USD 46.05 Billion in 2015 and is expected to reach USD 75.17 Billion by 2021 with a CAGR of 10.3 %. This market will increase tremendously during forecast period.
View Full Report @ http://www.marketdataforecast.com/market-reports/europe-generic-drugs-market-2185/
Generic drugs are drugs that have exactly same active ingredient as branded drug and yields the same therapeutic action. It is the same in dosage, Strength, Safety, and quality as that of brand name drug. Generic drugs are much less expensive and they can only be used after the patent of brand name drug expires. Generic drugs are also known as abbreviated drugs.
Download Free Sample Report @ http://www.marketdataforecast.com/market-reports/europe-generic-drugs-market-2185/request-sample
The cost-effectiveness of abbreviated drugs has given it a competitive lead over branded drugs in the market. Key driving factor for generic drugs is patent expiry for branded drugs. Patent for Branded drugs with sales of up to USD 135 billion was expired in 2015. Nearly USD 150 Billion worth of patents for branded drugs will expire by 2020 which will give generic drugs a huge advantage. One more trend which influences market growth is outsourcing. Growing Key players in this region is a huge advantage for this market. Vendors are using outsourcing as a strategy to reduce their capital which will be an advantage to generic drugs. Only restraint for this market is rigid rules setup by FDA for approval of these drugs and the threat of counterfeit drugs.
Avail Discount @ http://www.marketdataforecast.com/market-reports/europe-generic-drugs-market-2185/request-discount
Generic drugs market is segmented into Biosimilars, Simple generic and Super generic. Based on therapeutic drugs, they are further segmented into Cardiovascular products, anti-infective products, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. Super generics are sold at higher price than their pure generic counterpart. Super generics account for 18% of total spending on generic drugs. But biosimilars are comparatively cost effective even among generic drugs. Biosimilar drugs is expected to have significant growth during the forecast period. Based on Geography, this region is further divided in to UK, Germany, Italy, France and Spain.
Buy now @ https://www.marketdataforecast.com/cart/buy-now/europe-generic-drugs-market-2185
Key players in this market are Ranbaxy Laboratories, Ltd, Actavis, Mylan, Inc., Industries, Ltd., Dr. Reddy’s Laboratories, Par Pharmaceutical, Inc., Sandoz International GmbH, Hospira, Inc., Apotex, Inc., Watson Pharmaceuticals, Ltd., Teva Pharmaceutical and others.
About Market Data Forecast: The publisher of this report is Market Data Forecast whose forte lies in Market research and Business Intelligence. Handling both individual and corporate clients across multiple business domains they offer syndicated/customized research to suit the client’s research objective. Their research reports section offers a wide variety of market studies ranging from all-encompassing comprehensive market studies to product specific niche markets covering Global among other regions of the global market as well. For more info kindly visit, www.marketdataforecast.com
Visit MarketDataForecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com
|
|
|
London, UK News by Region
|
|
|
Press Release Writing & Distribution
We write and distribute your press release to online major media outlets for only 199. Fast turn around.
More on
Press Release Writing & Distribution
LONDON, UK TV NEWS
|